Name | Role | Date | Shares | Price | Value |
---|---|---|---|---|---|
James E. Flynn | Director | 2025-02-27 | 353,249 | $0.93 | $328.87kBuy |
James E. Flynn | Director | 2025-02-27 | 353,249 | $0.93 | $328.87kBuy |
Fibrosis Foundation Cystic | 10% Owner | 2024-05-15 | 4,778,265 | $0.00 | $4.78kBuy |
Orbimed Israel Biofund GP Limited Partnership | 10% Owner | 2024-05-15 | 24,344 | $0.38 | $9.28kSell |
Orbimed Israel Biofund GP Limited Partnership | 10% Owner | 2024-05-15 | 9,280,408 | $0.24 | $2.26MBuy |
Name | Hold | Shares | Value | Type |
---|---|---|---|---|
Orbimed Israel Biofund GP Limited Partnership | 55.17% | 13,773,653 | $7.44M | Insider |
Erez Chimovits | 18.53% | 4,626,978 | $2.50M | Insider |
Chidozie Ugwumba | 12.00% | 2,997,025 | $1.62M | Insider |
James E. Flynn | 9.99% | 2,494,108 | $1.35M | Insider |
Takeda Pharmaceutical Co Ltd | 9.90% | 2,470,935 | $1.33M | Insider |
Jonas Grossman | 8.33% | 2,080,217 | $1.12M | Insider |
Orbimed Advisors LLC | 7.16% | 1,787,767 | $965.39k | Institution |
Fibrosis Foundation Cystic | 7.16% | 1,787,758 | $965.39k | Insider |
Deerfield Management Company LP Series C | 7.16% | 1,787,610 | $965.31k | Institution |
Nantahala Capital Management LLC | 6.93% | 1,730,600 | $934.52k | Institution |